Atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the... | May 11, 2023

Related Keywords

Berlin ,Germany ,Allan Malievsky ,Deuterated Etifoxine ,Stephen Bardin ,Society For Biological Psychiatry ,Development Rd Expenses ,Life Sciences ,Exchange Commission ,Securities Exchange ,Hercules Capital Inc ,Cognitive Impairment Associated ,Pivotal Trial ,Florian Brand ,Pipeline Recent Highlights ,Pro Cognitive Neuromodulator ,Cognitive Battery ,Anxiety Disorders ,Biological Psychiatry ,Psilocybin Therapy ,Anorexia Nervosa ,Cash Equivalents ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Hercules Capital ,Financial Condition ,Atai Life Sciencesnv Stock Exchange ,News ,Information ,Press Release ,First ,Patient ,Hosed ,N ,The ,Hase ,Tb ,Study ,F ,Cognitive ,Impairment ,Ssociated ,Ith ,Resented ,D ,Data ,Rom ,Ompleted , ,Which ,Uggest Atai Nl0015000dx5 ,